Menu
Search
|

Menu

Close
X

Genmab A/S GEN.CO (Copenhagen Stock Exchange)

1,241.00 DKK
+41.00 (+3.42%)
As of 3:59 PM GMT
chart
Previous Close 1,200.00
Open 1,205.00
Volume 480,488
3m Avg Volume 341,750
Today’s High 1,241.00
Today’s Low 1,179.50
52 Week High 1,489.00
52 Week Low 994.80
Shares Outstanding (mil) 61.16
Market Capitalization (mil) 85,016.77
Forward P/E 63.56
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 19 analysts

KEY STATS

Revenue (mm, DKK)
FY17
2,365
FY16
1,816
FY15
1,133
EPS (DKK)
FY17
17.753
FY16
19.181
FY15
12.782
*Note: Units in Millions of Danish Krone
**Note: Units in Danish Krone

KEY RATIOS

Price to Earnings (TTM)
vs sector
63.56
32.90
Price to Sales (TTM)
vs sector
36.70
5.77
Price to Book (MRQ)
vs sector
15.59
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
0.00
16.52
LT Debt to Equity (MRQ)
vs sector
0.00
12.22
Return on Investment (TTM)
vs sector
29.46
14.43
Return on Equity (TTM)
vs sector
29.47
16.13

EXECUTIVE LEADERSHIP

Mats Pettersson
Independent Chairman of the Board, Since 2013
Salary: --
Bonus: --
Jan van de Winkel
President and Chief Executive Officer, Since 2010
Salary: --
Bonus: --
Anders Gersel Pedersen
Deputy Chairman of the Board, Since 2015
Salary: --
Bonus: --
David Eatwell
Executive Vice President, Chief Financial Officer, Since 2008
Salary: --
Bonus: --
Judith Klimovsky
Executive Vice President, Chief Development Officer, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

Kalvebod Brygge 43
KOEBENHAVN V     1560

Phone:

Genmab A/S is a Denmark-based biotechnology company. It is engaged in the development of differentiated human antibody therapeutics for the treatment of cancer, as well as other medical conditions, such as relapsing remitting multiple sclerosis. Its product pipeline includes a number of research and development projects in various phases, including Ofatumumab for the treatment of, among others, Waldenstrom’s Macroglobulinemia and chronic lymphocytic leukemia; Daratumumab, for the treatment of multiple myeloma; Teprotumumab, aimed at active thyroid eye disease, and HuMax-TF-ADC for the treatment of solid cancers, among others. Additionally, the Company has more than ten product candidates in pre-clinical phase. It develops its projects under worldwide co-development and commercialization agreements with GlaxoSmithKline, H. Lundbeck A/S, Roche, and Seattle Genetics, among others. It has three wholly owned subsidiaries in the Netherlands and the United States.

SPONSORED STORIES